Mumbai, July 3 -- Biocon Biologics(BBL), a fully integrated global biosimilars company and subsidiary of Biocon, today announced that the European Commission (EC) has granted marketing authorisation in the European Union (EU) for Vevzuo(R) and Evfraxy(R) biosimilars of Denosumab.
Published by HT Digital Content Services with permission from Capital Market....